Compare TULP & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TULP | FEMY |
|---|---|---|
| Founded | 1990 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0M | 11.5M |
| IPO Year | 2026 | 2021 |
| Metric | TULP | FEMY |
|---|---|---|
| Price | $2.31 | $1.22 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.75 |
| AVG Volume (30 Days) | 4.4K | ★ 104.8K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.71 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,800,000.00 | $2,293,313.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $294.61 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 40.77 |
| 52 Week Low | $2.00 | $0.29 |
| 52 Week High | $4.99 | $6.29 |
| Indicator | TULP | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 42.34 | 36.99 |
| Support Level | $2.00 | $0.33 |
| Resistance Level | $2.50 | $1.55 |
| Average True Range (ATR) | 0.14 | 0.14 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 53.09 | 36.46 |
Bloomia Holdings Inc is a specialty agricultural company focused on making and managing its ag investments in the U.S. and internationally. The Company is the majority owner of Bloomia, one of the largest producers of fresh-cut tulips in the United States.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.